Skip to main content

Table 1 Epidemiological characteristics, treatment and follow-up of enrolled patients

From: The prognosis of recurrent low-grade endometrial stromal sarcoma: a retrospective cohort study

  Values
Extrauterine LGESS, n (%) 9 (16.1)
Mitotic activity < 5 per 10 high power field, n (%) 45 (80.4)
Immunohistochemical staining, n (%)  
 Positive estrogen receptor 51 (91.1)
 Positive progesterone receptor 50 (89.3)
DFS after first treatment (months), median (range) 34.7 (5–188)
Ages at diagnosis of recurrence (years), median (range) 43.3 (17–70)
Extrapelvic recurrence, n (%) 23 (41.1)
Symptomatic recurrence, n (%) 23 (41.1)
Repeated surgeries for first recurrence, n (%) 50 (89.3)
 With residual lesions, n/n (%) 3/50 (6.0)
Chemotherapy for recurrence, n (%) 17 (30.4)
Radiotherapy for recurrence, n (%) 18 (32.1)
Hormone treatment for recurrence, n (%) 26 (46.4)
Fertility sparing  
 Fertility sparing after first treatment, n (%) 9 (16.1)
 Fertility sparing after first recurrence, n (%) 6 (10.7)
Ovarian preservation  
 Ovarian preservation after first treatment, n (%) 35 (62.5)
 Ovarian preservation after first recurrence, n (%) 9 (16.1)
Loss to follow-up, n (%) 13 (23.2)
Repeated recurrence, n/n (%) 30/43 (69.8)
 PFI after last treatment for first recurrence (months), median (range) 18.3 (1–121)
Death, n/n (%) 12/43 (27.9)
 OS after diagnosis of first recurrence (months), median (range) 43.6 (3–349)
  1. DFS, disease-free survival; PFI, progression-free interval; LGESS, low-grade endometrial stromal sarcoma